SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as investors express concerns about its correlation to Bitcoin's price and the dilutive effect of share issuances for further BTC acquisitions. The community is actively debating the company's business model and potential outcomes post-earnings, with some fearing a significant drop. Concerns about a potential collapse, comparisons to past financial downturns, and the influence of short sellers are also prevalent in discussions.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards as investors react to increased AI spending plans and a large one-time tax charge, overshadowing otherwise positive earnings results. Despite a record-breaking bond offering, the community is debating whether this dip represents a buying opportunity or reflects deeper concerns about Meta's capital expenditures. Some traders are closely watching key support levels and potential for a rebound, while others express skepticism about the long-term profitability of Meta's AI investments.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors brace for its earnings report, with the central focus being ad revenue and AI partnerships. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to META's recent performance, while also highlighting high short interest as a possible catalyst for a squeeze. Some traders express caution about the stock's valuation and potential for a selloff if earnings disappoint.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid buyout speculation and renewed interest from SpaceX, driving community excitement about a potential bidding war. The community is buzzing about possible high buyout figures and the implications for existing partnerships, including the Apple deal. Discussions also involve Globalstar's spectrum value and potential combinations with other industry players.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as investors anticipate upcoming earnings, with some expecting a significant move in either direction. Community members are actively discussing potential outcomes and strategizing based on technical analysis and unusual options activity. The broader tech sector and potential AI developments remain a key focus for Apple's future growth.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards, with the community expressing concerns about recent price action and continued stock dilution; some are questioning the company's overall strategy and the credibility of bullish forecasts, while others remain optimistic about the long-term potential of Ethereum and BMNR's accumulation strategy.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors gear up for earnings, with debates focusing on AWS growth and its potential impact on the stock's direction. The community is weighing the impact of AI investments and recent layoffs, while considering Amazon's overall standing within the broader tech landscape. Some anticipate a post-earnings surge, while others brace for a potential downturn, highlighting the uncertainty surrounding the report.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid speculation of a potential acquisition, fueled by a recent report suggesting the company is in talks for a significant deal. The community is actively discussing potential buyout prices and speculating on which pharmaceutical company could be the acquirer, with some pointing to the company's oncology pipeline as a key attraction. Despite the positive price movement, some investors remain cautious, citing upcoming earnings and potential legal liabilities.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards as investors react to concerns about slowing revenue growth and declining traffic, particularly among younger, lower-income consumers. The community is discussing the impact of these trends on the company's future, with some suggesting the need for strategic changes and others viewing the dip as a buying opportunity. There is also debate around the value proposition offered by Chipotle compared to competitors amidst rising costs.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending as the community discusses a potential short squeeze and re-evaluation after a robust third quarter and raised FY25 EBITDA guidance, with some anticipating analyst upgrades and significant price movement. Bullish investors are expressing confidence in the company's fundamentals, while others debate potential resistance levels and optimal strategies. High trading volume and positive cash flow reports are also contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A takeover or a large partnership was reportedly on the table for the company.</li><li>According to a report from Seeking Alpha, citing Stat News, the nature of the potential agreement, while unclear, is one of “significant scope.”&nbsp;</li><li>Moderna has been seeking to expand its portfolio since COVID-19 infections dropped globally. &nbsp;</li></ul>Shares of Moderna (MRNA) jumped 17% on Thursday afternoon following reports that the company held talks with at least one large drugmaker.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker">report</a> from Seeking Alpha, citing Stat News, a takeover or a large partnership was being considered for the company. The nature of the potential agreement, while unclear, is one of “significant scope,” the report added. &nbsp;<h2 class="st-heading-2">Moderna’s Weakening Sales</h2>In August, the vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.For the second quarter, the company reported revenues of $142 million, down from the $241 million reported in the corresponding quarter of 2024. The company attributed the revenue drop to lower COVID-19 vaccine sales. It noted that its demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons, due to the seasonal nature of the infection.Sales of Moderna’s COVID-19 vaccine came in at $114 million in the three months through the end of June, while its Respiratory Syncytial Virus vaccine sales were negligible.The company has been seeking to expand its portfolio since COVID-19 infections dropped globally from their peak in the early 2020s. The company hit a peak yearly revenue of $19.3 billion in 2022, when COVID-19 &nbsp;infections were high, which then dropped to $3.2 billion in 2024. The shares have borne the brunt, dropping over 57% in the past five years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user sounded cautious about the company’s upcoming earnings.<stembedurl>https://stocktwits.com/Galba/message/634362215</stembedurl>Since the start of the year, the company’s shares have declined by approximately 30%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bmy-ceo-expects-cancer-drug-opdivo-to-drive-strong-sales-in-2025/cLG8bFRR3xp">BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal

According to a report from Seeking Alpha, citing Stat News, Moderna has held talks with at least one large drugmaker. 

Equity

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna Moderna - which has been around less than 10 years and 'somehow' convinced the government to mandate their mRNA jabs for...

Wall Street's top analyst calls for the week of October 20, 2024

Yahoo Finance looks at Wall Street's top analyst call for the week of October 20, 2024. 0:00 Ebay, Deckers Outdoor, Intel October 24, 2025 1:37 Tesla, Zions Bancorp, Moderna October 23, 2025 3:25...

Moderna (MRNA) Outperforms Broader Market: What You Need to Know

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

<ul class="summary-bullets"><li>Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.</li><li>The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.</li><li>Moderna reaffirmed its 2025 guidance and breakeven goal for 2028, noting the vaccine was expected to be cash-flow negative that year.</li></ul>Moderna Inc. shares fell 4% in after-hours trading on Wednesday after the biotech company said its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, failed to meet its primary efficacy endpoint in a late-stage trial.<h2 class="st-heading-2">Phase 3 Trial Misses Target</h2>The Phase 3 trial was designed to determine if the vaccine can prevent CMV infection among seronegative women aged 16-40. Moderna stated that the vaccine efficacy was substantially below the company's expectations and fell between 6 and 23% depending on the case definition used. The company will not continue the development of mRNA-1647 for the prevention of congenital CMV.“Today's announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV,” said CEO Stephane Bancel in a statement. “We will share full results with the scientific community in hopes that our learnings contribute to the continued pursuit of a CMV vaccine.”<h2 class="st-heading-2">Focus Shifts To Transplant Patients</h2>Moderna will further evaluate mRNA-1647 in a Phase 2 trial for bone marrow transplant recipients, who can experience serious complications when CMV is reactivated. The company said it will investigate the vaccine’s ability to suppress CMV reactivation in this high-risk population.The company said mRNA-1647 was well-tolerated with no safety concerns identified by the trial’s monitoring board.<h2 class="st-heading-2">No Impact On Financial Outlook</h2>Moderna said the setback is not expected to impact its 2025 financial guidance or its path to breakeven in 2028. The company had expected low revenue for the CMV vaccine in the near term before investments in the market and for the product to be cash-flow negative in 2028.<h2 class="st-heading-2">Stocktwits Users Debate Cash Burn, Oncology Focus After Vaccine Failure</h2>On Stocktwits, retail sentiment for Moderna was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:978/137;" src="https://news.stocktwits-cdn.com/mrna_ss_jpg_45aec4f522.webp" alt="mrna ss.jpg" width="978" height="137"><figcaption>MRNA sentiment and message volume as of October 22 | Source: Stocktwits</figcaption></figure>One user suggested the company’s decision to discontinue the CMV program might actually help reduce its cash burn, saying the move could allow Moderna to concentrate more effectively on its oncology pipeline.<stembedurl>https://stocktwits.com/pfh_investing/message/633326630</stembedurl>Another user expressed concern that the company’s spending remained unsustainable, describing its cash burn as “endless.”<stembedurl>https://stocktwits.com/KK_KK/message/633344767</stembedurl>A third bearish user took a harsher view, warning that the stock could fall below $5, after revealing they held two sold naked calls expiring this week.<stembedurl>https://stocktwits.com/georgeyann/message/633359261</stembedurl><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.

Market Wrap- Top Stocks: Tesla, Intuitive Surgical

The earnings season has sent the market into a scramble. Strong reports from major banks last week sent the market soaring, followed by Tuesday's estimate miss from Netflix and electric-vehicle...

Moderna (MRNA) Dips More Than Broader Market: What You Should Know

Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.

Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

R&D spending now can have big payoffs later for companies

Just how long have people been saying you have to spend money to make money"?Historians maintain that this particular proverb goes all that way back to the Roman playwright Titus Maccius Plautus, who...

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRNA News

MRNAModerna Inc